As previously communicated, the Brazilian research group at the Hematology and Transfusion Medicine Center at the University of Campinas/Hemocentro-UNICAMP in São Paulo has concluded that Foxy-5 could inhibit several oncogenic processes that occur in the blood cancer disease Acute Myeloid Leukaemia (AML) by inhibiting cell growth in a pre-clinical model. According to the research group, Foxy-5 appears to be a promising candidate for the treatment of AML. The article’s heading is 'The anti-tumour effects of WNT5A against haematological malignancies'[1].
 

“Our group is very excited by our results, and we all look forward to our continued research with Foxy-5”, says Dr Maura Lima, head of the research group.

"It is very valuable that the results are now also published in more detail and in such a prominent journal. I look forward to continued collaboration with this group.", says Pernilla Sandwall, CEO.
 

The results have previously been presented as an abstract at an annual scientific meeting organised by the American Society of Hematology (ASH) and are included in the journal Blood's supplement from the meeting. The work of the Brazilian research team has led to WntResearch's previous patent application for Foxy-5 for the treatment of AML.
 

For further information:

Pernilla Sandwall, VD
E-mail: pernilla.sandwall@wntresearch.com

About Wntresearch AB 

WntResearch is developing a completely new type of cancer drug that inhibits the ability of tumour cells to spread in the body and form metastases. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 per cent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.

WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com. Follow WntResearch on Linked in